NL-OMON36904已完成不适用
A DOUBLE-BLIND, PLACEBO-CONTROLLED DOSE ESCALATION STUDY OF THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF A SUBCUTANEOUS DOSE OF SHK-186 IN HEALTHY SUBJECTS - ShK-186 SAD study
Kineta One0 个研究点目标入组 56 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 56
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- healthy male and female subjects
- •- 18-45 yrs, inclusive
- •- BMI: 18.0-30.0 kg/m2, inclusive and weigh > 50 kg
- •- the volunteers did not smoke during at least 30 days prior to the screening
排除标准
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.
研究者
相似试验
已完成
不适用
A DOUBLE-BLINDED, PLACEBO-CONTROLLED, SINGLE DOSE AND MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND PROOF OF CONCEPT OF DM-199 IN HEALTHY SUBJECTS AND PATIENTS WITH TYPE 2 DIABETES MELLITUSType2 Diabetes Mellitus: bloodglucose.10018424NL-OMON40545DiaMedica Inc.96
进行中（未招募）
不适用
A study on the safety, tolerability and the effect of DM-199 on the body, a new agent for the treatment of Diabetes Mellitus Type 2, after single- and multiple dosing in healthy volunteers and Diabetes Mellitus Type 2 patients.Diabetes Mellitus type 2MedDRA version: 16.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2013-000225-30-NLDiaMedica USA Inc.
进行中（未招募）
不适用
A DOUBLE-BLIND, DOSE-RANGE, PLACEBO CONTROLLED STUDYOF THE EFFECTS OF PST2238 VS. PLACEBO IN PATIENTSWITH STABLE, UNCOMPLICATED, ESSENTIAL HYPERTENSION.EUCTR2004-000415-26-ITSIGMA-TA440
进行中（未招募）
1 期
A double-blind, placebo-controlled study with increasing doses of chemically modified tree pollen drops in patients suffering from allergicinflammation of the conjunctiva and rhinitis which are caused by tree pollen allergens.Treatment of tree pollen-induced allergic rhinoconjunctivitisMedDRA version: 20.0Level: LLTClassification code 10001728Term: Allergic rhinoconjunctivitisSystem Organ Class: 100000004853EUCTR2017-003063-34-DEofarma S.p.A.48
进行中（未招募）
1 期
Intranasal booster of IRO-203 to people had new corona virus vaccines, phase 1 study.Prevention of SARS-CoV-2 infectionJPRN-jRCT2031230116Tsubaki Atsushi84